Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion

Archives of Iranian Medicine

Volumn 11, Issue 5, 2008, Pages 539-543

  Farahvash, Mohammad Sadegh ^a,b   Farahvash, Mohammad Medhi ^a   Moradimogadam, Marzieh ^a   Mohammadzadeh, Shiva ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Iran)

Author keywords

Central retinal vein occlusion (CRVO); Dalteparin; Heparin; Low molecular weight heparin (LMWH); Neovascularization of iris (NVI)

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; ECCHYMOSIS; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; MALE; RANDOMIZED CONTROLLED TRIAL; SUBRETINAL NEOVASCULARIZATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION; VITREOUS HEMORRHAGE;

ASPIRIN; DALTEPARIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IRIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RETINAL VEIN OCCLUSION;

EID: 63449113321     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Magargal LE, Brown GC, Augsburger JJ, Parrish RK 2nd. Neovascular glaucoma following central retinal vein obstruction. Ophthalmology. 1981; 88: 1095-1101.
2. Magargal LE, Donoso LA, Sanborn GE. Retinal ischemia and risk of neovascularization following central retinal vein obstruction. Ophthalmology. 1982; 89: 1241-1245.
3. Murdoch IE, Rosen PH, Shilling JS. Neovascular response in ischaemic central retinal vein occlusion after panretinal photocoagulation. Br J Ophthalmol. 1991; 75: 459-461.
4. Sanborn GE, Venous occlusive disease of retina. In: Tasman W, Jaeger E, eds. Duane's Clinical Ophthalmology. Chapter 15. Philadelphia: Lippincott. 1996; 3.
5. Glacet-Bernard A, Kuhn D. Treatment of recent-onset central retinal vein occlusion with intravitreal TPA: a pilot study. Br J Ophthalmol. 2000; 84: 609-613.
6. Kohner EM, Laatikainen L, Oughton J. The management of central retinal vein occlusion. Ophthalmology. 1983; 90: 484-487.
7. Glacet-Bernard A, Zourdani A, Milhoub M, Maraqua N, Coscas G, Soubrane G. Effect of isovolumic hemodilution in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2001; 239: 909-914.
8. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol. 1994; 118: 421-429.
9. Vallée JN, Aymard A, Paques M, Santiago PY, Gaudric A, Merland JJ. Value of local ophthalmic artery fibrinolysis in severe forms of central retinal vein occlusion. J Radiol.2001; 82: 137-144.
10. Kohner EM, Pettit JE, Hamilton AM, Bulpitt CJ, Dollery CT. Streptokinase in central retinal vein occlusion. Br Med J. 1976; 1: 550-553.
11. Cekiç O, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissman H, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina. 2005; 25: 846 - 850.
12. Bashshur ZF, Ma'luf RN, Allam S, Jurdi FA, Haddad RS, Noureddin BN. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol. 2004; 122: 1137-1140.
13. Ghazi NG, Noureddine B, Haddad RS, Jurdi FA, Bashshur ZF. Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. Retina. 2003; 23: 780-784.
14. Garcíia-Arumíi J, Boixadera A, Martinez-Castillo V, Castillo R, Dou A, Corcostegui B. Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol. 2003; 121: 1385-1391.
15. Kwok AK, LeeVY, Lai TY, Hon C. Laser induced chorioretinal venous anastomosis in ischaemic central retinal vein occlusion. Br J Ophthalmol. 2003; 87: 1043-1044.
16. Zambarakji HJ, Ghazi-Nouri S, Schadt M, Bunce C, Hykin PG, Charteris DG. Vitrectomy and radial optic neurotomy for central retinal vein occlusion: effects on visual acuity and macular anatomy. Graefes Arch Clin Exp Ophthalmol. 2005; 243: 397-405.
17. Vannas S, Orma H. Experience of treating retinal venous occlusion with anticoagulant and anti sclerotic therapy. AMA Arch Ophthalmol. 1957; 58: 812-828.
18. Haas A, Walzl M, Faulborn J, Walzl B, Berglöff J, Eckhardt M. Heparin-induced extracorporeal LDL precipitation (H.E.L.P.). A new therapeutic possibility in vascular occlusion of the retina--initial results [in German]. Ophthalmologe. 1994; 91: 283-287.
19. Furuta M, Sekiryu T, Sato H, Fujiwara T. Warfarin potassium for impending central retinal vein occlusion [in Japanese]. Nippon Ganka Gakkai Zasshi. 1999; 103: 124-128.
20. Handin RA, Anticoagulant, fibrinolytic and antiplatelet therapy. In: Braunward E, Fausi AS, eds. Harrison's Principles of Internal Medicine. 15th ed. New York: Mc Graw-Hill; 2001; 1: 758-760.
21. Harker LA, Antithrombotic therapy. In: Bennet JC, Plum VF, eds. Cecil Textbook of Medicine. 21th ed. Philadelphia: Saunders; 2000; 119-122.
22. Romanowska B, Goszcz A, Grodzinska L, Bieroń K, Kostka-Trabka E. Evaluation of fraxiparine efficacy in the treatment of retinal vein occlusion [in Polish]. Klin Oczna. 1999; 101: 451-454.
23. Kasymova MS. Results of fraxiparine and ticlid therapy of acute retinal vessels occlusion [in Russian]. Vestn Oftalmol. 1998; 114: 21-24.
24. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med. 1992; 326: 800-806.
25. Hirsh J. Heparin. N Engl J Med.1991; 394: 1565-1574.
26. Magargal LE, Brown GC, Augsburger JJ, Donoso LA. Efficacy of panretinal photocoagulation in preventing neovascular glaucoma following ischemic central retinal vein obstruction. Ophthalmology. 1982; 89: 780-784.
27. Laatikainen L. A prospective follow-up study of panretinal photocoagulation in preventing neovascular glaucoma following ischaemic central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1983; 220:236-239.
28. Duker JS, Brown GC. The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction. Ophthalmology. 1989; 96: 92-95.
29. Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES. Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study. Graefes Arch Clin Exp Ophthalmol. 1990; 228: 281-296.
30. Brown GC, Magargal LE, Schachat A, Shah H. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology. 1995; 102: 1434-1444.
31. Farahvash MS, Moghaddam MM, Moghimi S, Mohammadzadeh S. Dalteparin in the management of recent-onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can J Ophthalmol. 2008; 43: 79-83.
32. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology. 1983; 90: 458-474.
33. Kilgore KS, Tanhehco EJ, Naylor KB, Lucchesi BR. Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion. J Pharmacol Exp Ther. 1999; 290: 1041-1047.
34. Kouretas PC, Kim YD, Cahill PA, Myers AK, To LN, Wang YN, et al. Heparin and nonanti-coagulant heparin preserve regional myocardial contractility after ischemiareperfusion injury. Role of nitric oxide. J Thorac Cardiovasc Surg. 1998; 115: 440-449.